摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(8-Bromoquinolin-6-yl)-2-methylpropanenitrile | 346630-01-1

中文名称
——
中文别名
——
英文名称
2-(8-Bromoquinolin-6-yl)-2-methylpropanenitrile
英文别名
——
2-(8-Bromoquinolin-6-yl)-2-methylpropanenitrile化学式
CAS
346630-01-1
化学式
C13H11BrN2
mdl
——
分子量
275.148
InChiKey
YRZWQVNIPHLRFX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.23
  • 拓扑面积:
    36.7
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    氮桥取代的8-芳基喹啉作为有效的PDE IV抑制剂。
    摘要:
    描述了人PDE IV酶的有效抑制剂。基于本文所述的SAR,将带有氮连接的侧链的取代的8-芳基喹啉类似物鉴定为有效的抑制剂。据报道,在有意识的豚鼠中,卵清蛋白诱导的支气管收缩试验中最好的类似物的药代动力学特征和体内功效。
    DOI:
    10.1016/j.bmcl.2006.02.043
  • 作为产物:
    参考文献:
    名称:
    Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: Structure–activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor
    摘要:
    The discovery and SAR of a new series of substituted 8-arylquinoline PDE4 inhibitors are herein described. This work has led to the identification of several compounds with excellent in vitro and in vivo profiles, including a good therapeutic window of emesis to efficacy in several animal models. Typical optimized compounds from this series are potent inhibitors of PDE4 (IC50 < 1 nM) and also of LPS-induced TNF-alpha release in human whole blood (IC50 < 0.5 mu M). The same compounds are potent inhibitors of ovalbumin-induced bronchoconstriction in conscious guinea pigs (EC50 < 0.1 mg/kg ip) but require a dose of about 10 mg/kg po in the squirrel monkey to produce an emetic response. From this series of compounds, 23a (L-454,560) was identified as an optimized compound. (c) 2005 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2005.08.036
点击查看最新优质反应信息

文献信息

  • Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
    申请人:——
    公开号:US20020143032A1
    公开(公告)日:2002-10-03
    Novel sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, 2-naphthalenesulfonic acid, hydrochloride acid, or benzenesulfonic acid salts of substituted 8-arylquinolines, wherein the aryl group at the 8-position contains a substituent substituted-alkenyl group, are PDE4 inhibitors.
    新型硫酸、甲磺酸、对甲苯磺酸、2-萘磺酸、盐酸或苯磺酸盐的取代8-芳基喹啉,其中8位的芳基基团包含一个取代烯丙基基团,是PDE4抑制剂。
  • [EN] SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS<br/>[FR] ARYLQUINONES INHIBITEURS DE PDE4 A SUBSTITUTION EN POSITION 8
    申请人:MERCK FROSST CANADA INC
    公开号:WO2003002118A1
    公开(公告)日:2003-01-09
    8-arylquinolines of formula(I) wherein the aryl group at the 8-position contains a meta two atom bridge to an optionally substituted phenyl or pyridyl group, are PDE4 inhibitors useful to treat asthma, chronic bronchitis, chronic obstructive pulmonary disease, arthritis, respiratory distress syndrome, allergic rhinitis, neurogenic inflammation, pain, rheumatoid arthritis, and other diseases. R1-R7 and Ar are as in claim 1.
    公式(I)中的8-arylquinolines,其中8位的芳基基团含有一个与可选取代的苯基或吡啶基团形成的间位两原子桥,是PDE4抑制剂,可用于治疗哮喘、慢性支气管炎、慢性阻塞性肺疾病、关节炎、呼吸窘迫综合症、过敏性鼻炎、神经源性炎症、疼痛、类风湿性关节炎和其他疾病。其中R1-R7和Ar如权利要求1所述。
  • Hetero-bridge substituted 8-arylquinoline pde4 inhibitors
    申请人:Gallant Michel
    公开号:US20050245513A1
    公开(公告)日:2005-11-03
    8-arylquinolines wherein the aryl group at the 8-position contains a meta one or two atom bridge to a phenyl, 5 or 6 member heteroaryl or fused bicyclic heteroaryl group, and wherein at least one of the bridge atoms is not carbon, are PDE4 inhibitors.
    8-芳基喹啉中,位于8位的芳基基团包含一个与苯、5或6成员杂环芳基或融合的双环杂环芳基群之间的一个或两个原子桥,且至少有一个桥中的原子不是碳,它们是PDE4抑制剂。
  • Substituted 8-arylquinolune pde4 inhibitors
    申请人:——
    公开号:US20040162314A1
    公开(公告)日:2004-08-19
    8-arylquinolines of formula (I) wherein the aryl group at the 8-position contains a meta two atom bridge to an optionally substituted phenyl or pyridyl group, are PDE4 inhibitors useful to treat asthma, chronic bronchitis, chronic obstructive pulmonary disease, arthritis, respiratory distress syndrome, allergic rhinitis, neurogenic inflammation, pain, rheumatoid arthritis, and other diseases. R 1 -R 7 and Ar are as in claim 1. 1
    公式(I)中的8-芳基喹啉,其中8位处的芳基团含有与可选取代苯基或吡啶基相连接的间位两个原子桥,是PDE4抑制剂,可用于治疗哮喘、慢性支气管炎、慢性阻塞性肺病、关节炎、呼吸窘迫综合症、过敏性鼻炎、神经源性炎症、疼痛、类风湿性关节炎和其他疾病。其中R1-R7和Ar如权利要求1.1所述。
  • 8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors
    申请人:Dube Daniel
    公开号:US20060223850A1
    公开(公告)日:2006-10-05
    Novel substituted 8-phenylquinolines represented by Formula (I), wherein the phenyl group at the 8-position contains an aryl or heteroaryl substituent in the meta position, are PDE4 inhibitors.
    小说代替了公式(I)所代表的8-苯基喹啉,其中8-位置的苯基含有一个在间位的芳基或杂环芳基取代基,是PDE4抑制剂。
查看更多